Diagnosis and Acute Management of Adolescent Cannabinoid Hyperemesis Syndrome: A Systematic Review
| Autor: | Robert M. Issenman, Jie Wei Zhu, Clarelle L. Gonsalves, April J. Kam |
|---|---|
| Přispěvatelé: | Pediatrics |
| Rok vydání: | 2020 |
| Předmět: |
Adult
Pediatrics medicine.medical_specialty Marijuana Abuse Adolescent Vomiting MEDLINE CINAHL Cochrane Library Substance use Adolescents 03 medical and health sciences 0302 clinical medicine 030225 pediatrics medicine Humans 030212 general & internal medicine Depression (differential diagnoses) Cannabis integumentary system Cyclic vomiting syndrome business.industry Cannabinoids Public Health Environmental and Occupational Health Syndrome medicine.disease Cannabinoid hyperemesis syndrome Marijuana Psychiatry and Mental health Treatment Outcome Pediatrics Perinatology and Child Health Inclusion and exclusion criteria Anxiety Female medicine.symptom Capsaicin business |
| Zdroj: | The Journal of adolescent health : official publication of the Society for Adolescent Medicine. 68(2) |
| ISSN: | 1879-1972 |
| Popis: | Purpose This study aimed to synthesize qualitative and quantitative data on the diagnosis and effective management of cannabinoid hyperemesis syndrome (CHS) in the adolescent population. Methods Using keywords, 1,334 studies published between December 1954 and December 2019 were extracted from MEDLINE via PubMed, Embase via OVID, CINAHL via EBSCO, Web of Science, and the Cochrane Library. Studies were evaluated by two independent reviewers using predetermined inclusion and exclusion criteria. Results The search yielded 148 studies for full-text review, of which 21 were included in this systematic review. A total of 10 articles were related to the diagnosis of CHS, while 11 articles discussed the treatment and management of adolescent cases of CHS. Conclusions CHS in the adolescent population fulfills the major and minor diagnostic criteria of CHS in the adult population; however, in adolescent patients, CHS may present more frequently in females, with the earliest reported case presenting at age 15 years. There appears to be a substantial proportion (21%) of adolescent patients diagnosed with CHS that have a history of anxiety and depression; however, higher quality studies to assess the prevalence are warranted. Although haloperidol and topical capsaicin cream may provide symptom relief in isolated cases, complete cessation of cannabis use is currently the only known effective treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect